

Global Guide of Coming Off-patent Agrochemical Active Ingredients

The Eighth Edition

August 2021

Researched & Prepared by:

Kcomber Inc.

Copyright by Kcomber Inc.

Any publication, distribution or copying of the content in this report is prohibited.

Contents

Executive summary	1
Methodology and scope	4
1 Profiles of coming off-patent herbicides	7
1.1 Aminopyralid	7
1.2 Pyrasulfotole	14
1.3 Pyroxasulfone	17
1.4 Pyroxsulam	21
1.5 Saflufenacil	27
1.6 Indaziflam	31
1.7 Cyprosulfamide	36
2 Profiles of coming off-patent insecticides	39
2.1 Chlorantraniliprole	39
2.2 Cyantraniliprole	49
2.3 Cyclaniliprole	54
2.4 Spirotetramat	57
3 Profiles of coming off-patent fungicides	63
3.1 Mandipropamid	63
3.2 Penflufen.....	70
3.3 Bixafen.....	74
3.4 Fluopyram.....	80
3.5 Isopyrazam	87
3.6 Sedaxane.....	91

LIST OF TABLES

Table 1.1-1 Patent information of aminopyralid in some countries/regions, as of July 2021

Table 1.1-2 Registration information of aminopyralid in Argentina, as of July 2021

Table 1.1-3 Registration information of aminopyralid in Australia, as of July 2021

Table 1.1-4 Registration information of aminopyralid in Belgium, as of July 2021

Table 1.1-5 Registration information of aminopyralid in Brazil, as of July 2021

Table 1.1-6 Registration information of aminopyralid in Canada, as of July 2021

Table 1.1-7 Registration information of aminopyralid in China, as of July 2021

Table 1.1-8 Registration information of aminopyralid in Denmark, as of July 2021

Table 1.1-9 Registration information of aminopyralid in Finland, as of July 2021

Table 1.1-10 Registration information of aminopyralid in France, as of July 2021

Table 1.1-11 Registration information of aminopyralid in Greece, as of July 2021

Table 1.1-12 Registration information of aminopyralid in the Netherlands, as of July 2021

Table 1.1-13 Registration information of aminopyralid in South Africa, as of April 2019

Table 1.1-14 Registration information of aminopyralid in Switzerland, as of July 2021

Table 1.1-15 Registration information of aminopyralid in the UK, as of July 2021

Table 1.1-16 Registration information of aminopyralid in Uruguay, as of July 2021

Table 1.1-17 Registration information of aminopyralid in the US, as of July 2021

Table 1.2-1 Patent information of pyrasulfotole in some countries/regions, as of July 2021

Table 1.2-2 Registration information of pyrasulfotole in Australia, as of July 2021

Table 1.2-3 Registration information of pyrasulfotole in Canada, as of July 2021

Table 1.2-4 Registration information of pyrasulfotole in South Africa, as of April 2019

Table 1.2-5 Registration information of pyrasulfotole in the US, as of July 2021

Table 1.3-1 Patent information of pyroxasulfone in some countries/regions, as of July 2021

Table 1.3-2 Registration information of pyroxasulfone in Argentina, as of July 2021

Table 1.3-3 Registration information of pyroxasulfone in Australia, as of July 2021

Table 1.3-4 Registration information of pyroxasulfone in Brazil, as of July 2021

Table 1.3-5 Registration information of pyroxasulfone in Canada, as of July 2021

Table 1.3-6 Registration information of pyroxasulfone in China, as of July 2021

Table 1.3-7 Registration information of pyroxasulfone in South Africa, as of April 2019

Table 1.4-1 Patent information of pyroxsulam in some countries/regions, as of July 2021

Table 1.4-2 Registration information of pyroxsulam in Australia, as of July 2021

Table 1.4-3 Registration information of pyroxsulam in Belgium, as of July 2021

Table 1.4-4 Registration information of pyroxsulam in Brazil, as of July 2021

Table 1.4-5 Registration information of pyroxsulam in Canada, as of July 2021

Table 1.4-6 Registration information of pyroxsulam in China, as of July 2021

Table 1.4-7 Registration information of pyroxsulam in Denmark, as of July 2021

Table 1.4-8 Registration information of pyroxsulam in France, as of July 2021

Table 1.4-9 Registration information of pyroxsulam in Greece, as of July 2021

Table 1.4-10 Registration information of pyroxsulam in the Netherlands, as of July 2021

Table 1.4-11 Registration information of pyroxsulam in South Africa, as of April 2019

Table 1.4-12 Registration information of pyroxsulam in Switzerland, as of July 2021

Table 1.4-13 Registration information of pyroxsulam in the UK, as of July 2021

Table 1.4-14 Registration information of pyroxsulam in the US, as of July 2021

Table 1.5-1 Patent information of saflufenacil in some countries/regions, as of July 2021

Table 1.5-2 Registration information of saflufenacil in Argentina, as of July 2021

Table 1.5-3 Registration information of saflufenacil in Australia, as of July 2021

Table 1.5-4 Registration information of saflufenacil in Brazil, as of July 2021

Table 1.5-5 Registration information of saflufenacil in Canada, as of July 2021

Table 1.5-6 Registration information of saflufenacil in Chile, as of July 2021

Table 1.5-7 Registration information of saflufenacil in China, as of July 2021

Table 1.5-8 Registration information of saflufenacil in South Africa, as of April 2019

Table 1.5-9 Registration information of saflufenacil in Uruguay, as of July 2021

Table 1.6-1 Patent information of indaziflam in some countries/regions, as of July 2021

Table 1.6-2 Registration information of indaziflam in Argentina, as of July 2021

Table 1.6-3 Registration information of indaziflam in Australia, as of July 2021

Table 1.6-4 Registration information of indaziflam in Brazil, as of July 2021
Table 1.6-5 Registration information of indaziflam in Canada, as of July 2021
Table 1.6-6 Registration information of indaziflam in Chile, as of July 2021
Table 1.6-7 Registration information of indaziflam in South Africa, as of April 2019
Table 1.6-8 Registration information of indaziflam in Uruguay, as of July 2021
Table 1.6-9 Registration information of indaziflam in the US, as of July 2021
Table 1.7-1 Patent information of cyprosulfamide in some countries/regions, as of July 2021
Table 1.7-2 Registration information of cyprosulfamide in Argentina, as of July 2021
Table 1.7-3 Registration information of cyprosulfamide in Belgium, as of July 2021
Table 1.7-4 Registration information of cyprosulfamide in Canada, as of July 2021
Table 1.7-5 Registration information of Cyprosulfamide in Chile, as of July 2021
Table 1.7-6 Registration information of cyprosulfamide in France, as of July 2021
Table 1.7-7 Registration information of cyprosulfamide in Greece, as of July 2021
Table 1.7-8 Registration information of cyprosulfamide in the Netherlands, as of July 2021
Table 2.1-1 Patent information of chlorantraniliprole in some countries/regions, as of July 2021
Table 2.1-2 Registration information of chlorantraniliprole in Australia, as of July 2021
Table 2.1-3 Registration information of chlorantraniliprole in Canada, as of July 2021
Table 2.1-4 Registration information of chlorantraniliprole in China, as of July 2021
Table 2.1-5 Registration information of Chlorantraniliprole in Finland, as of July 2021
Table 2.1-6 Registration information of chlorantraniliprole in France, as of July 2021
Table 2.1-7 Registration information of chlorantraniliprole in Greece, as of July 2021
Table 2.1-8 Registration information of chlorantraniliprole in the Netherlands, as of July 2021
Table 2.1-9 Registration information of chlorantraniliprole in South Africa, as of April 2019
Table 2.1-10 Registration information of chlorantraniliprole in Switzerland, as of July 2021
Table 2.1-11 Registration information of chlorantraniliprole in the UK, as of July 2021
Table 2.1-12 Registration information of chlorantraniliprole in Uruguay, as of July 2021
Table 2.1-13 Registration information of chlorantraniliprole in the US, as of July 2021
Table 2.2-1 Patent information of cyantraniliprole in some countries/regions, as of July 2021
Table 2.2-2 Registration information of cyantraniliprole in Argentina, as of July 2021
Table 2.2-3 Registration information of cyantraniliprole in Australia, as of July 2021
Table 2.2-4 Registration information of cyantraniliprole in Belgium, as of July 2021
Table 2.2-5 Registration information of cyantraniliprole in Canada, as of July 2021
Table 2.2-6 Registration information of cyantraniliprole in China, as of July 2021
Table 2.2-7 Registration information of cyantraniliprole in Finland, as of July 2021
Table 2.2-8 Registration information of cyantraniliprole in France, as of July 2021
Table 2.2-9 Registration information of cyantraniliprole in Greece, as of July 2021
Table 2.2-10 Registration information of cyantraniliprole in the Netherlands, as of July 2021
Table 2.2-11 Registration information of cyantraniliprole in South Africa, as of April 2019
Table 2.2-12 Registration information of cyantraniliprole in the UK, as of July 2021
Table 2.2-13 Registration information of cyantraniliprole in Uruguay, as of July 2021
Table 2.2-14 Registration information of cyantraniliprole in the US, as of July 2021
Table 2.3-1 Patent information of cyclaniliprole in some countries/regions, as of July 2021
Table 2.3-2 Registration information of cyclaniliprolen in Australia, as of July 2021
Table 2.3-3 Registration information of cyclaniliprole in Canada, as of July 2021

Table 2.3-4 Registration information of cyclaniliprole in the US, as of July 2021

Table 2.4-1 Patent information of spirotetramat in some countries/regions, as of July 2021

Table 2.4-2 Registration information of spirotetramat in Australia, as of July 2021

Table 2.4-3 Registration information of spirotetramat in Canada, as of July 2021

Table 2.4-4 Registration information of Spirotetramat in Chile, as of July 2021

Table 2.4-5 Registration information of spirotetramat in China, as of July 2021

Table 2.4-6 Registration information of spirotetramat in Denmark, as of July 2021

Table 2.4-7 Registration information of spirotetramat in France, as of July 2021

Table 2.4-8 Registration information of spirotetramat in Greece, as of July 2021

Table 2.4-9 Registration information of spirotetramat in the Netherlands, as of July 2021

Table 2.4-10 Registration information of spirotetramat in the Switzerland, as of July 2021

Table 2.4-11 Registration information of spirotetramat in the UK, as of July 2021

Table 2.4-12 Registration information of spirotetramat in Uruguay, as of July 2021

Table 2.4-13 Registration information of spirotetramat in the US, as of July 2021

Table 3.1-1 Patent information of mandipropamid in some countries/regions, as of July 2021

Table 3.1-2 Registration information of mandipropamid in Argentina, as of July 2021

Table 3.1-3 Registration information of mandipropamid in Australia, as of July 2021

Table 3.1-4 Registration information of mandipropamid in Belgium, as of July 2021

Table 3.1-5 Registration information of mandipropamid in Brazil, as of July 2021

Table 3.1-6 Registration information of mandipropamid in Canada, as of July 2021

Table 3.1-7 Registration information of mandipropamid in Chile, as of July 2021

Table 3.1-8 Registration information of mandipropamid in China, as of July 2021

Table 3.1-9 Registration information of mandipropamid in Denmark, as of July 2021

Table 3.1-10 Registration information of mandipropamid in Finland, as of July 2021

Table 3.1-11 Registration information of mandipropamid in France, as of July 2021

Table 3.1-12 Registration information of mandipropamid in Greece, as of July 2021

Table 3.1-13 Registration information of mandipropamid in the Netherlands, as of July 2021

Table 3.1-14 Registration information of mandipropamid in South Africa, as of April 2019

Table 3.1-15 Registration information of mandipropamid in Switzerland, as of July 2021

Table 3.1-16 Registration information of mandipropamid in the UK, as of July 2021

Table 3.1-17 Registration information of mandipropamid in the US, as of July 2021

Table 3.2-1 Patent information of penflufen in some countries/regions, as of July 2021

Table 3.2-2 Registration information of penflufen in Australia, as of July 2021

Table 3.2-3 Registration information of penflufen in Belgium, as of July 2021

Table 3.2-4 Registration information of penflufen in Canada, as of July 2021

Table 3.2-5 Registration information of penflufen in Chile, as of July 2021

Table 3.2-6 Registration information of penflufen in China, as of July 2021

Table 3.2-7 Registration information of penflufen in Finland, as of July 2021

Table 3.2-8 Registration information of penflufen in the Netherlands, as of July 2021

Table 3.2-9 Registration information of penflufen in the UK, as of July 2021

Table 3.2-10 Registration information of penflufen in the US, as of July 2021

Table 3.3-1 Patent information of bixafen in some countries/regions, as of July 2021

Table 3.3-2 Registration information of bixafen in Argentina, as of July 2021

Table 3.3-3 Registration information of bixafen in Australia, as of July 2021

Table 3.3-4 Registration information of bixafen in Belgium, as of July 2021
Table 3.3-5 Registration information of Bixafen in Canada, as of July 2021
Table 3.3-6 Registration information of bixafen in Chile, as of July 2021
Table 3.3-7 Registration information of bixafen in Denmark, as of July 2021
Table 3.3-8 Registration information of bixafen in Finland, as of July 2021
Table 3.3-9 Registration information of bixafen in France, as of July 2021
Table 3.3-10 Registration information of bixafen in the Netherlands, as of July 2021
Table 3.3-11 Registration information of bixafen in South Africa, as of April 2019
Table 3.3-12 Registration information of bixafen in Switzerland, as of July 2021
Table 3.3-13 Registration information of bixafen in the UK, as of July 2021
Table 3.3-14 Registration information of bixafen in Uruguay, as of July 2021
Table 3.3-15 Registration information of bixafen in the US, as of July 2021
Table 3.4-1 Patent information of fluopyram in some countries/regions, as of July 2021
Table 3.4-2 Registration information of fluopyram in Australia, as of July 2021
Table 3.4-3 Registration information of fluopyram in Belgium, as of July 2021
Table 3.4-4 Registration information of fluopyram in Brazil, as of July 2021
Table 3.4-5 Registration information of fluopyram in Canada, as of July 2021
Table 3.4-6 Registration information of fluopyram in China, as of July 2021
Table 3.4-7 Registration information of fluopyram in Denmark, as of July 2021
Table 3.4-8 Registration information of fluopyram in Finland, as of July 2021
Table 3.4-9 Registration information of fluopyram in France, as of July 2021
Table 3.4-10 Registration information of fluopyram in Greece, as of July 2021
Table 3.4-11 Registration information of fluopyram in the Netherlands, as of July 2021
Table 3.4-12 Registration information of fluopyram in South Africa, as of April 2019
Table 3.4-13 Registration information of fluopyram in Switzerland, as of July 2021
Table 3.4-14 Registration information of fluopyram in the UK, as of July 2021
Table 3.4-15 Registration information of fluopyram in the US, as of July 2021
Table 3.5-1 Patent information of isopyrazam in some countries/regions, as of July 2021
Table 3.5-2 Registration information of isopyrazam in Argentina, as of July 2021
Table 3.5-3 Registration information of isopyrazam in Australia, as of July 2021
Table 3.5-4 Registration information of isopyrazam in Belgium, as of July 2021
Table 3.5-5 Registration information of isopyrazam in China, as of July 2021
Table 3.5-6 Registration information of isopyrazam in Finland, as of July 2021
Table 3.5-7 Registration information of isopyrazam in France, as of July 2021
Table 3.5-8 Registration information of isopyrazam in Greece, as of July 2021
Table 3.5-9 Registration information of isopyrazam in the Netherlands, as of July 2021
Table 3.5-10 Registration information of isopyrazam in the UK, as of July 2021
Table 3.5-11 Registration information of isopyrazam in Uruguay, as of July 2021
Table 3.6-1 Patent information of sedaxane in some countries/regions, as of July 2021
Table 3.6-2 Registration information of sedaxane in Argentina, as of July 2021
Table 3.6-3 Registration information of sedaxane in Australia, as of July 2021
Table 3.6-4 Registration information of sedaxane in Canada, as of July 2021
Table 3.6-5 Registration information of sedaxane in Chile, as of July 2021
Table 3.6-6 Registration information of sedaxane in China, as of July 2021



- Table 3.6-7 Registration information of sedaxane in Denmark, as of July 2021
- Table 3.6-8 Registration information of sedaxane in Finland, as of July 2021
- Table 3.6-9 Registration information of sedaxane in France, as of July 2021
- Table 3.6-10 Registration information of sedaxane in Greece, as of July 2021
- Table 3.6-11 Registration information of sedaxane in the UK, as of July 2021
- Table 3.6-12 Registration information of sedaxane in Uruguay, as of July 2021
- Table 3.6-13 Registration information of sedaxane in the US, as of July 2021

LIST OF FIGURES

- Figure 1.1-1 Chemical structure of aminopyralid
- Figure 1.2-1 Chemical structure of pyrasulfotole
- Figure 1.3-1 Chemical structure of Pyroxasulfone
- Figure 1.4-1 Chemical structure of pyroxulam
- Figure 1.5-1 Chemical structure of saflufenacil
- Figure 1.7-1 Chemical structure of cyprosulfamide
- Figure 2.1-1 Chemical structure of chlorantraniliprole
- Figure 2.2-1 Chemical structure of cyantraniliprole
- Figure 2.3-1 Chemical structure of cyclaniliprole
- Figure 2.3-2 Route for synthesizing cyclaniliprole
- Figure 2.4-1 Chemical structure of spirotetramat
- Figure 2.4-2 Route for synthesizing spirotetramat
- Figure 3.1-1 Chemical structure of mandipropamid
- Figure 3.2-1 Chemical structure of penflufen
- Figure 3.3-1 Chemical structure of bixafen
- Figure 3.4-1 Chemical structure of fluopyram
- Figure 3.5-1 Chemical structure of isopyrazam
- Figure 3.6-1 Chemical structure of sedaxane

1. Introduction

Global Guide of Coming Off-patent Agrochemical Active Ingredients, finished in August 2021, is CCM's eighth edition report on coming off-patent agrochemicals in the world. This report contains profiles of 17 active ingredients (7 herbicides, 4 insecticides, 6 fungicides) whose patents will expire in 2021–2028.

Among the 17 active ingredients, 10 of which had been registered in at least ten countries among the 17 target ones as of August 2021.

Among the 17 target countries, there were 2 countries where at least 15 active ingredients had been registered as of August 2021.

In this report, CCM will introduce global guide of coming off-patent agrochemical active ingredients from the following aspects:

- √ Basic information
- √ Chemical structure
- √ History
- √ Synthesis route
- √ Application
- √ Physical & safety data
- √ Patent information
- √ Registration information

If you want more information, please feel free to contact us.

Tel: +86-20-37616606 Fax: +86-20-37616968

Email: econtact@cnchemicals.com

2. Methodology and scope

Guide of Coming Off-patent Agrochemical Active Ingredients, finished in August 2021, is CCM's eighth edition report on coming off-patent agrochemicals in the world. This report contains profiles of 17 active ingredients (7 herbicides, 4 insecticides, 6 fungicides) whose patents will expire during 2021–2028.

As for each active ingredient, this report introduces its basic information, chemical structure, history, synthesis route, application, physical & safety data, patent information and registration information.

Methodology

- Desk research

The sources of desk research are various and include published magazines, journals, government statistics, industrial statistics, customs statistics, association seminars as well as information from the internet. A lot of work went into compiling and analysing the information obtained.

- Data processing and presentation

The data collected and compiled were sourced from:

- Published articles from Chinese periodicals, magazines, journals, and the third-party databases
- Government statistics & customs statistics
- Comments from industrial experts
- Valotracer (CCM's innovative database)
- Professional databases from other sources
- Information from the internet

The data from various channels have been combined to make this report as precise and scientific as possible. Throughout the process, a series of internal discussions were held in order to analyse the data and draw conclusions from it.

Unit

- ha: hectare
- d: day
- h: hour
- g/ha: gram/hectare
- l/kg: litre/kilogram

Note

- "/" in this reports means that there is no information showed.
- N/A in this report refers to unavailable.

3. Executive summary

Global Guide of Coming Off-patent Agrochemical Active Ingredients, finished in August 2021, is CCM's eighth edition report on coming off-patent agrochemicals in the world. This report contains profiles of XXXX active ingredients (XXXX herbicides, XXXX insecticides and XXXX fungicides) whose patents will expire in 2021–2028.

Among the XXXX active ingredients, XXXX of which had been registered in at least ten countries among the XXXX target ones as of August 2021.

Among the XXXX target countries, there were XXXX countries where at least XXXX active ingredients had been registered as of August 2021—XXXX and XXXX.

Table Pesticides to come off-patent in 2021–2028

Active ingredient	Developer	Patent expiry date	Application
Herbicides			
XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX
Insecticides			
XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX
Fungicides			
XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX

Source: CCM

4. What's in this report

Note: Key data/information in this sample page is hidden, while in the report it is not.

.....

1 Profiles of coming off-patent herbicides

1.1 Aminopyralid

- Basic information

IUPAC name: 4-Amino-3,6-dichloropyridine-2-carboxylic acid

CAS No.: 150114-71-9


Formula: $C_6H_4Cl_2N_2O_2$

Typical formulation: aminopyralid 240g/L SL

Formulation type: SL, SC, EC and WG

Trade name: Lancelot, Tombo, Tocon

Figure 1.1-1 Chemical structure of aminopyralid



- History

Aminopyralid was first registered for use in 2005 in the US by Dow AgroSciences LLC.

- Application

...

- Physical & safety data

...

Toxicity

...

Environmental profile

...

- Patent information

Table 1.1-1 Patent information of aminopyralid in some countries/regions, as of July 2021

Country/region	Patent No.	Time
China	XXXX	XXXX
The European Union	XXXX	XXXX
The US	XXXX	XXXX

Source: EPO & SIPO

- Registration information

As of July 2021, aminopyralid had been registered in 16 countries among the 17 target countries.

Table 1.1-2 Registration information of aminopyralid in Argentina, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: SENASA

Table 1.1-3 Registration information of aminopyralid in Australia, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: APVMA

Table 1.1-4 Registration information of aminopyralid in Belgium, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: Phytoweb

Table 1.1-5 Registration information of aminopyralid in Brazil, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: MAPA

Table 1.1-6 Registration information of aminopyralid in Canada, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: Health Canada

Table 1.1-7 Registration information of aminopyralid in China, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: ICAMA

Table 1.1-8 Registration information of aminopyralid in Denmark, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: SEGES

Table 1.1-9 Registration information of aminopyralid in Finland, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: TUKES

Table 1.1-10 Registration information of aminopyralid in France, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: E-phy

Table 1.1-11 Registration information of aminopyralid in Greece, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: Hellenic Republic Ministry of Reconstruction of Production, Environmental and Energy Rural Development

Table 1.1-12 Registration information of aminopyralid in the Netherlands, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: CTGB

Table 1.1-13 Registration information of aminopyralid in South Africa, as of April 2019

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: DAFF

Table 1.1-14 Registration information of aminopyralid in Switzerland, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: BLW

Table 1.1-15 Registration information of aminopyralid in the UK, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: HSE

Table 1.1-16 Registration information of aminopyralid in Uruguay, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: MGAP

Table 1.1-17 Registration information of aminopyralid in the US, as of July 2021

Active ingredient	Type of formulation	Content	Product name	Registrant
XXXX	XXXX	XXXX	XXXX	XXXX
...
XXXX	XXXX	XXXX	XXXX	XXXX

Source: NPIRS Public

1.2 Pyrasulfotole

- Basic information

...

If you want more information, please feel free to contact us

Tel: +86-20-37616606 Fax: +86-20-37616968

Email: econtact@cnchemicals.com